PMV Pharmaceuticals logo

PMV PharmaceuticalsNASDAQ: PMVP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 September 2020

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$83.98 M
-92%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
25%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$1.63$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PMVP Latest News

Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
zacks.com03 June 2024 Sentiment: POSITIVE

PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
businesswire.com29 May 2024 Sentiment: POSITIVE

BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--Foundation Medicine and PMV Pharma partner to develop FoundationOne®CDx as a companion diagnostic for PMV Pharma's rezatapopt.

PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research16 October 2023 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for PMV Pharmaceuticals, Inc. (PMVP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
GlobeNewsWire11 October 2023 Sentiment: POSITIVE

PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston, Massachusetts. The poster will contain updated clinical data from the study as of September 5, 2023.

Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet
Zacks Investment Research30 August 2023 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 182.6% in PMV Pharmaceuticals, Inc. (PMVP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
GlobeNewsWire06 June 2023 Sentiment: POSITIVE

PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference taking place in Dana Point, California June 12-15, 2023. The company will also be available to meet one-on-one with institutional investors at the conference. Details on the fireside chat can be found below.

What type of business is PMV Pharmaceuticals?

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

What sector is PMV Pharmaceuticals in?

PMV Pharmaceuticals is in the Healthcare sector

What industry is PMV Pharmaceuticals in?

PMV Pharmaceuticals is in the Biotechnology industry

What country is PMV Pharmaceuticals from?

PMV Pharmaceuticals is headquartered in United States

When did PMV Pharmaceuticals go public?

PMV Pharmaceuticals initial public offering (IPO) was on 25 September 2020

What is PMV Pharmaceuticals website?

https://www.pmvpharma.com

Is PMV Pharmaceuticals in the S&P 500?

No, PMV Pharmaceuticals is not included in the S&P 500 index

Is PMV Pharmaceuticals in the NASDAQ 100?

No, PMV Pharmaceuticals is not included in the NASDAQ 100 index

Is PMV Pharmaceuticals in the Dow Jones?

No, PMV Pharmaceuticals is not included in the Dow Jones index

When was PMV Pharmaceuticals the previous earnings report?

No data

When does PMV Pharmaceuticals earnings report?

The next expected earnings date for PMV Pharmaceuticals is 08 November 2024